Jake Becraft, a former grad student in biological engineering at MIT, had a groundbreaking idea that could revolutionize cancer treatment: the ability to turn genes on and off like light switches. He envisioned creating “circuits” using messenger RNA (mRNA) to program cancerous tumors to reveal themselves to the body’s immune system. This cutting-edge concept led him to co-found Strand Therapeutics in Cambridge, Massachusetts, with Tasuku Kitada.
After eight years of dedicated research and development, Strand has shown promising results in its preliminary phase 1 clinical trial. The company’s first programmable mRNA drug not only proved to be safe but also demonstrated the ability to shrink tumors in cancer patients who had exhausted all other treatment options. This unexpected success led to a significant milestone for the company, as it raised $153 million in new venture funding, with Kinnevik leading the investment round.
The total funding for Strand now stands at $250 million, with a valuation estimated at $550 million. This achievement is remarkable for a clinical-stage biotech firm amidst a challenging fundraising environment for the biotech industry. With plans to bring its first therapy to market by 2030, Strand aims to leverage its innovative mRNA technology to develop personalized medicines for various diseases beyond cancer, such as heart disease.
While mRNA technology gained widespread recognition through the success of Covid-19 vaccines from Moderna and BioNTech, Strand’s approach differs significantly. Instead of creating antigens for viruses, Strand’s mRNA therapeutics instruct tumors to produce signals that make them visible to the immune system, enabling the body to fight back against cancer. This targeted approach has shown promising results in clinical trials, with tumors shrinking in response to treatment.
Jake Becraft, now the CEO of Strand, envisions a future where mRNA and genetic medicines play a crucial role in revolutionizing healthcare. By targeting specific cells and delivering therapeutic proteins where needed, without causing toxicity, the company aims to redefine cancer treatment. With additional clinical research in the pipeline and plans for commercialization by 2030, Strand is at the forefront of harnessing the potential of mRNA technology to develop innovative therapies.
As Becraft and his team continue to push the boundaries of science and medicine, they remain committed to unlocking the full potential of mRNA therapeutics in treating a wide range of diseases. With a strong focus on precision targeting and personalized medicine, Strand Therapeutics is poised to reshape the landscape of healthcare and make a lasting impact on patient outcomes.
